RxDoctor Payments Data

Thomas Mendler, MD

Hospitalist · Baton Rouge, LANPI 1861712895

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $432 and has fallen 65.9% since, to $148 in 2024.

$1,221in general payments, 2019–2025

Across 72 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$255
  • Novartis$248
  • Otsuka America Pharmaceutical, Inc.$125
  • Pfizer$95
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
  • Merck$66
  • plus $353 from 11 others

What the payments were for

  • Food & beverage$1,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,221 in reported general payments places this provider in the 85th percentile of 301 hospitalist providers in Louisiana.

See all hospitalist providers in Louisiana

Medicare billing

Part B allowed, 2024
$42,970
Medicare patients
172
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cefdinir11$154
Furosemide13$36

Paid to pharmacies, not to this prescriber.

Other hospitalist in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →